Effects of Ranolazine in Patients with Chronic Angina in Patients with and Without Percutaneous Coronary Intervention for Acute Coronary Syndrome: Observations from the MERLIN-TIMI 36 Trial

Clinical Cardiology

Volumn 38, Issue 8, 2015, Pages 469-475

  Gutierrez, Jorge A ^a   Karwatowska Prokopczuk, Ewa ^b   Murphy, Sabina A ^a   Belardinelli, Luiz ^b   Farzaneh Far, Ramin ^b   Walker, Gennyne ^b   Morrow, David A ^a   Scirica, Benjamin M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Gilead Science   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; RANOLAZINE; SODIUM CHANNEL BLOCKING AGENT;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK REDUCTION; ACUTE CORONARY SYNDROME; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; ANGINA PECTORIS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; RANOLAZINE; RECURRENCE; SODIUM CHANNEL BLOCKERS; TREATMENT OUTCOME;

EID: 84939463843     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22425     Document Type: Article

References (19)

1. Go AS, Mozaffarian D, Roger VL, et al., Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013; 127: e6-e245.
2. Kones R., Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization. Vasc Health Risk Manag. 2010; 6: 749-774.
3. Anderson JL, Adams CD, Antman EM, et al., 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 61: e179-347.
4. Chaitman BR,. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation. 2006; 113: 2462-2472.
5. Chaitman BR, Skettino SL, Parker JO, et al., Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004; 43: 1375-1382.
6. Wilson SR, Scirica BM, Braunwald E, et al., Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol. 2009; 53: 1510-1516.
7. Chaitman BR, Pepine CJ, Parker JO, et al., Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004; 291: 309-316.
8. Stone PH, Gratsiansky NA, Blokhin A,; ERICA Investigators. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006; 48: 566-575.
9. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al., Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007; 297: 1775-1783.
10. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al., Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. Am Heart J. 2006; 151:1186.e1-e9.
11. Spertus JA, Dawson J, Masoudi FA, et al., Prevalence and predictors of angina pectoris one month after myocardial infarction. Am J Card. 2006; 98: 282-288.
12. Alexander KP, Cowper PA, Kempf JA, Lytle BL, Peterson ED,. Profile of chronic and recurrent angina pectoris in a referral population. Am J Card. 2008; 102: 1301-1306.
13. Antzelevitch C, Belardinelli L, Zygmunt AC, et al., Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004; 110: 904-910.
14. Murphy E, Cross H, Steenbergen C,. Sodium regulation during ischemia versus reperfusion and its role in injury. Circulation Res. 1999; 84: 1469-1470.
15. Imahashi K, Kusuoka H, Hashimoto K, et al., Intracellular sodium accumulation during ischemia as the substrate for reperfusion injury. Circulation Res. 1999; 84: 1401-1406.
16. Imahashi K, Mraiche F, Steenbergen C, et al., Overexpression of the Na+/H+ exchanger and ischemia-reperfusion injury in the myocardium. Am J Physiol Heart Circ Physiol. 2007; 292: H2237-H2247.
17. Kusuoka H, Camilion de Hurtado MC, Marban E,. Role of sodium/calcium exchange in the mechanism of myocardial stunning: protective effect of reperfusion with high sodium solution. J Am Coll Cardiol. 1993; 21: 240-248.
18. Kusuoka H, Marban E,. Cellular mechanisms of myocardial stunning. Ann Rev Physiol. 1992; 54: 243-256.
19. Weisz G, Farzaneh-Far R, Ben-Yehuda O, et al., Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (RIVER-PCI) trial. Am Heart J. 2013; 166:953-959.e3.